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OPEN
ORIGINAL ARTICLE
Preclinical safety and tolerability of a repeatedly administered
human leishmaniasis DNA vaccine
O Riede1, K Seifert2, D Oswald1, A Endmann1, C Hock3, A Winkler4, FJ Salguero5,6, M Schroff1, SL Croft2 and C Juhls1
The leishmaniases are a complex of vector-borne diseases caused by protozoan parasites of the genus Leishmania. LEISHDNAVAX is
a multi-antigen, T-cell epitope-enriched DNA vaccine candidate against human leishmaniasis. The vaccine candidate has been
proven immunogenic and showed prophylactic efﬁcacy in preclinical studies. Here, we describe the safety testing of LEISHDNAVAX
in naive mice and rats, complemented by the demonstration of tolerability in Leishmania-infected mice. Biodistribution and
persistence were examined following single and repeated intradermal (i.d.) administration to rats. DNA vectors were distributed
systemically but did not accumulate upon repeated injections. Although vector DNA was cleared from most other tissues within
60 days after the last injection, it persisted in skin at the site of injection and in draining lymph nodes. Evaluation of single-dose and
repeated-dose toxicity of the vaccine candidate after i.d. administration to naive, non-infected mice did not reveal any safety
concerns. LEISHDNAVAX was also well tolerated in Leishmania-infected mice. Taken together, our results substantiate a favorable
safety proﬁle of LEISHDNAVAX in both naive and infected animals and thus, support the initiation of clinical trials for both
preventive and therapeutic applications of the vaccine.
Gene Therapy (2015) 22, 628–635; doi:10.1038/gt.2015.35
INTRODUCTION
The leishmaniases are a complex of diseases caused by protozoan
parasites of the genus Leishmania with up to 1.6 million cases
reported worldwide annually1 and ~ 350 million people at risk to
develop leishmaniasis.2 It is estimated that the most severe form,
visceral leishmaniasis (VL), causes up to 40 000 deaths per year.1
Measures to control transmission of the parasite were of limited
success to date. Despite advances in treatment of VL over the last
decade, drug toxicity and heat stability, difﬁcult routes of
administration and variation in drug efﬁcacy between endemic
areas remain issues to be fully solved. A preventive and
therapeutic leishmaniasis vaccine prospectively represents the
most cost-effective and successful measure to control the
leishmaniases worldwide.3
Immunity to the intracellular parasite Leishmania is associated
with T-cell-mediated immune responses.4 DNA vaccines are
particularly able to deliver antigens into the major histocompat-
ibility complex class I processing pathway, thereby inducing CD8
cytotoxic T-cell immune responses,5,6 necessary for clearance of
Leishmania. In addition, CD4 T cells and B cells are activated by
DNA vaccines. Hence, this vaccination technology is a promising
approach for developing a leishmaniasis vaccine.7
An appropriate preclinical safety proﬁle of a vaccine candidate
has to be established prior to initiation of clinical phase 1 studies.
The US Food and Drug Administration (FDA) and the World Health
Organization recommend the evaluation of distribution and
persistence of DNA vaccines as well as their local reactogenicity
and systemic toxicity.8,9 Results of corresponding studies suggest
that DNA vaccines are safe,10,11 which has been conﬁrmed in
several clinical trials.12 However, immunogenicity of DNA vaccines
was often modest in humans, necessitating better delivery
methods and improved vaccine antigen expression.12 In addition,
safety concerns prompted avoidance of antibiotic resistance
genes and other selection markers for plasmid propagation.13
State-of-the-art plasmids are consequently more efﬁcacious, safer
and smaller than classical plasmids.14 Minimalistic Immunogeni-
cally Deﬁned Gene Expression (MIDGE) vectors represent one of
the most rigorous concepts for improvement.15 MIDGE vectors are
small linear double-stranded DNA (dsDNA) molecules, solely
containing sequences required for their function in vivo and no
bacterial plasmid backbone sequences as they have been
shown to negatively impact transgene expression and
immunogenicity.16,17 MIDGE-Th1 vectors are MIDGE vectors with
a short peptide (PKKKRKVEDPYC) covalently attached, enhancing
the immune responses to encoded antigens.18,19 Recently,
preclinical data on biodistribution and toxicity of MIDGE and
MIDGE-Th1 vectors have been published,20,21 indicating an
excellent safety proﬁle after a single administration.
LEISHDNAVAX is a mixture of ﬁve MIDGE-Th1 vectors each
encoding a different Leishmania antigen: KMP11, CPA, CPB, P74
(elongation factor 1-alpha) or TSA.22 Antigen selection and sequence
design followed a novel rational approach. In a series of animal
experiments it was demonstrated that LEISHDNAVAX is immuno-
genic and effective against challenge with Leishmania donovani, the
causative agent of VL.22 The vaccine is aimed to be administered to
humans in both preventive and therapeutic settings.
Here, we present comprehensive preclinical safety and toler-
ability data for LEISHDNAVAX. A repeated-dose toxicity study in
naive mice and a biodistribution and persistence study in rats
were performed. Moreover, the effect of LEISHDNAVAX
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administration on parasite burden and standard tolerability
parameters in mouse models of VL were evaluated. In all studies,
potential cumulative effects of repeated dosing of LEISHDNAVAX
were addressed to allow for a better risk-assessment prior to
multi-dose clinical trials.
RESULTS
LEISHDNAVAX is systemically distributed after intradermal
administration
Biodistribution of the vaccine was assessed in rats after
intradermal (i.d.) injection of a 120 μg dose. Total DNA was
extracted from tissue samples taken 24 h post injection and
MIDGE-Th1 vector DNA quantiﬁed using a quantitative PCR (qPCR)
assay. Vector DNA was found in a varying number of animals per
group and in all tissues except for bone marrow (Figure 1a). The
vector copy numbers per μg total DNA ranged from 4.04 × 103
(geometric mean, ovaries, 4/5 animals positive) to 2.55 × 109
(geometric mean, skin of injection site, all animals positive).
Comparable distribution pattern after single or repeated
administration
Next, we tested whether repeated administration alters the
distribution pattern or causes accumulation of vector DNA in
tissues. One hundred and twenty micrograms of LEISHDNAVAX
were administered to rats i.d. at the same site four times at weekly
intervals. Vector DNA was quantiﬁed in total DNA extracted from
tissue samples collected 24 h after the last injection. Distribution
patterns and amounts of vector DNA were comparable 24 h after
single and repeated injection (Figures 1a and b). Copy numbers
per μg total DNA ranged from 4.63 × 103 (geometric mean, lung
tissue, 5/10 animals positive) to 4.50 × 107 (geometric mean, skin
of injection site, all animals positive).
MIDGE-Th1 vectors persist at injection site and in draining lymph
nodes
Persistence of MIDGE-Th1 vectors was examined 14 days and
60 days post treatment. Fourteen days after four injections
LEISHDNAVAX was cleared from the majority of organs (Figure 1c).
High vector copy numbers per μg total DNA were found in skin of
injection site (all animals positive, geometric mean: 3.45 × 106
copies) and in inguinal lymph nodes (7/10 animals positive,
geometric mean: 2.88 × 104 copies). Sixty days after four injections,
MIDGE-Th1 vectors were cleared from most tissues but persisted
in inguinal lymph nodes (5/10 animals positive, geometric mean:
1.44 × 104 copies) and skin of injection site (all animals positive,
geometric mean: 6.93 × 105 copies) (Figure 1d).
Figure 1. Biodistribution and persistence of LEISHDNAVAX following single and multiple i.d. injections. Groups of 10 Wistar rats (5 male, 5
female) were injected once (a) or four times in weekly intervals (b–d) with 120 μg LEISHDNAVAX. Tissue samples were taken and processed
24 h (a and b), 14 days (c) or 60 days (d) after the last injection. Vector copy numbers were determined by qPCR. Single animal data and
geometric mean values are given in log scale. Dotted lines indicate lower the limit of quantiﬁcation LLOQ. Lnn ax: axillary lymph nodes; Lnn
ing: inguinal lymph nodes; Lnn mes mesenteric lymph nodes; M. femoris: quadriceps muscle of thigh.
Safety and tolerability of a leishmaniasis DNA vaccine
O Riede et al
629
© 2015 Macmillan Publishers Limited Gene Therapy (2015) 628 – 635
LEISHDNAVAX is well tolerated in naive animals
To assess toxicity of LEISHDNAVAX in naive mice, sterile
phosphate-buffered saline (PBS, placebo) and ascending doses
of the vaccine were injected either once or ﬁve times in weekly
intervals (Table 1). LEISHDNAVAX was well tolerated at all doses
tested. No animal died during the in-life phase, and no change in
behavior or external appearance of the animals was noted.
Comparing placebo-treated to LEISHDNAVAX-treated animals, no
differences were observed in body weight, food and drinking
water consumption, ophthalmological and auditory examinations,
urinalysis, organ weights and the neurological screening. No local
intolerance reactions were noted after single or repeated vaccine
dosing. Minor deviations in single animals/groups for few blood
parameters (large unstained cells, albumin/globulin ratio, α-
amylase) were classiﬁed as not vaccine-related. Macroscopic post
mortem examination of organs revealed an enlarged spleen in a
single male animal 1 day after single administration of 100 μg
LEISHDNAVAX, which possibly indicated the activation of the
lymphatic system. In all animals the histological ﬁndings were
within the normal range of variation. No LEISHDNAVAX-related
morphological lesions were found. No signs of auto-immune
reactions were observed, and there were no elevated levels of
serum antibodies against dsDNA detected.
Biological activity of the vaccine lot was proven by induction of
antigen-speciﬁc serum immunoglobulin G (IgG) in mice of satellite
groups (Table 1). A dose-dependent increase of LEISHDNAVAX-
speciﬁc IgG levels was observed (Figure 2), in line with data from
efﬁcacy studies as previously reported.22
Rats receiving the vaccine during the biodistribution study did
not exhibit any vaccine-related local or systemic signs of toxicity,
and also necropsy did not reveal any vaccine-related toxicity.
LEISHDNAVAX is well tolerated in L. donovani-infected mice
Tolerability of LEISHDNAVAX and effects on visceral parasite
burden were evaluated in BALB/c and C57BL/6 mice. Groups of
mice infected with L. donovani were injected with one, two or
three doses of 100 μg LEISHDNAVAX or PBS in weekly intervals.
Parasite burden was evaluated seven days and 29 days after the
last injection. No signiﬁcant difference in hepatic or splenic
parasite burden was found between groups receiving equal
numbers of injections of PBS or LEISHDNAVAX. In both treatment
groups infection with L. donovani followed the known kinetic23
with distinct organ-speciﬁc growth patterns in livers and spleens
of infected mice. Figure 3 shows the parasite burden as
determined in the BALB/c and one C57BL/6 experiment.
No signiﬁcant difference in weights between PBS and
LEISHDNAVAX-treated groups of mice was observed. Serum
samples from mice, which had received three injections of PBS
or LEISHDNAVAX, were subjected to analyses of standard
biochemical parameters; alanine transaminase, aspartate amino-
transferase, urea and creatinine. No signiﬁcant differences
between PBS and LEISHDNAVAX-treated groups were found for
these parameters in BALB/c mice. Signiﬁcant differences were
found in levels of creatinine in C57BL/6 mice in two separate
experiments. However, neither the time point nor the direction of
difference were consistent between experiments (Table 2).
Histological analysis of livers and spleens in repeated experiments
and the kidney, heart and lung in a single experiment
(C57BL/6 mice) revealed similar lesions in all animals (PBS and
LEISHDNAVAX treated) in terms of location and severity. Lesions
were consistent with infection and included severe granuloma-
tous hepatitis and splenitis with intralesional parasites, granulo-
matous/interstitial pneumonia and interstitial nephritis and
glomerulonephritis.
DISCUSSION
Biodistribution and persistence of DNA vaccines are studied to
estimate the duration of antigen expression and the risk of vector
integration into host genomic DNA.8,9 We examined the
biodistribution of LEISHDNAVAX after a single and, in contrast to
previously published results,20,21 also after a series of four
injections at weekly intervals. This condensed application
scheme is relevant for clinical approaches with: (i) a limited
number of injections over a longer period of time as accepted
for prophylactic vaccinations and (ii) vaccination regimes
requiring more injections in shorter intervals, for example,
therapeutic vaccinations. In line with recommendations of the
US FDA,8 organ and tissue samples were taken at several time
points following injections and vector DNA was quantiﬁed using
quantitative PCR.
Twenty-four hour after single or repeated injection, MIDGE-Th1
vector DNA was detected in almost all organs and tissues
examined, suggesting that it was distributed systemically, most
likely via the lymphatic system and the blood stream. A similar
distribution pattern has been described for MIDGE-Th1 vectors
Table 1. Scheme of toxicity study in naive mice
DNA dose
(μg)
Number
of doses
Day(s) of
immunization
Day(s) of
samplinga
after last dosing
Number of
animals (males,
females)
10 1 1 1 10 (5, 5)
5 1, 8, 15, 22, 29 1, 14 20 (10, 10)
5b 1, 8, 15, 22, 29 1, 14 20 (10, 10)
50 1 1 1 10 (5, 5)
5 1, 8, 15, 22, 29 1, 14 20 (10, 10)
5b 1, 8, 15, 22, 29 1, 14 20 (10, 10)
100 1 1 1 10 (5, 5)
5 1, 8, 15, 22, 29 1, 14, 61 30 (15, 15)
5b 1, 8, 15, 22, 29 1, 14, 61 30 (15, 15)
Placebo 1 1 1 10 (5, 5)
5 1, 8, 15, 22, 29 1, 14, 61 30 (15, 15)
5b 1, 8, 15, 22, 29 1, 14, 61 30 (15, 15)
aPer day of sampling, ﬁve male and ﬁve female animals per group were
killed. bSatellite group to assess biologic activity of the vaccine lot and
induction of antibodies against dsDNA.
Figure 2. Immunogenicity of ascending LEISHDNAVAX doses in
mice. Groups of 10 BALB/c mice (5 male, 5 female) were immunized
i.d. at the tail base ﬁve times in weekly intervals with either PBS or
LEISHDNAVAX (10, 50 or 100 μg per dose). Fourteen days after the
last immunization LEISHDNAVAX-speciﬁc antibodies (total IgG) in
sera were quantiﬁed by ELISA using plates coated with a mixture of
recombinant LEISHDNAVAX antigens. ***P⩽ 0.001 (Student's t-test);
n.s.: not signiﬁcant.
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encoding Hepatitis B surface antigen,21 indicating that distribu-
tion of MIDGE-Th1 vectors is independent of the encoded
protein as previously reported for plasmid DNA vectors.11
Systemic distribution at early time points has also been shown
for naked plasmid DNA upon i.m. and i.d administration.24,25 In
accordance with other reports,11,26,27 the highest vector amounts
were detected in samples taken from the site of injection.
Consistently, lymph nodes draining the site of injection
contained the second highest copy numbers, probably due to
skin immune cells taking up DNA at the site of injection and
migrating to the lymph nodes.
At day 14 after the fourth injection, vectors were cleared from
nearly all organs except from skin and inguinal lymph nodes.
Whereas the amount of vector DNA in skin samples was ~ 10-fold
lower compared with 24 h after the last injection, vector copy
numbers in inguinal lymph node samples were reduced
~ 100-fold. This ﬁnding is in line with reports on i.d.-administered
plasmid DNA vaccines,27–29 suggesting that plasmids and
MIDGE-Th1 vectors (21 and this report) follow a similar pattern
of distribution and persistence.
MIDGE-Th1 vector DNA was not cleared from skin and inguinal
lymph nodes within 60 days after four injections. Although this
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Figure 3. Parasite burden in BALB/c and C57BL/6 mice following administration of single and repeated doses of LEISHDNAVAX and PBS.
Parasite burden expressed in Leishman-Donovan Units (LDU) is shown for BALB/c mice in spleens (a) and livers (b) (n= 8–9 mice per group)
and for C57BL/6 mice in spleens (c) and livers (d) (n= 4–8 mice per group). Mice were infected on day 0, treated once (day 7), twice (day 7 and
14) or three times (day 7, 14 and 21), respectively, with 100 μg LEISHDNAVAX per dose or PBS. Parasite burden was determined 7 days after the
last treatment and in addition, for two groups of C57BL/6 mice receiving either three LEISHDNAVAX or PBS injections, 29 days after the third
treatment (day 50 post infection). White bars represent PBS-treated groups and dark gray bars LEISHDNAVAX-treated groups, error bars
indicate s.e.m. Differences between groups were statistically not signiﬁcant based on a one-way ANOVA followed by Bonferroni’s multiple
comparison’s test, which compared groups that had received the same number of injections of PBS or LEISHDNAVAX (P40.05).
Table 2. Biochemical serum parameters of L. donovani-infected and PBS- or LEISHDNAVAX (DNA)-treated mice
Experiment/
mouse strain
Treatment
(3 doses)
Sampling (days post
Infection)
Mice n Urea mean± s.e.m.
(mmol l− 1)
Creatinine mean± s.e.m.
(μmol l− 1)
ALT mean± s.e.m.
(U l− 1)
AST mean± s.e.m.
(U l− 1)
1/BALB/c PBS 28 8 5.5± 0.3 9.6± 0.8 60.0± 8.1 90.0± 35.7
DNA 28 7 5.4± 0.2 11.7± 1.9 74.5± 17.2 194.6± 103
2/C57BL/6 PBS 28 5 7.3± 0.5 18.0± 0.9a 144.6± 25 176.1± 35.5
DNA 28 5 6.8± 0.4 13.4± 1.2a 122.0± 16.2 134.1± 15.1
3/C57BL/6 PBS 28 8 6.2± 0.2 10.7± 0.6 142.8± 13.7 162.5± 12.1
DNA 28 7 5.6± 0.3 13.9± 1.4 156.6± 20.1 188.9± 35.2
PBS 50 7 7.0± 0.4 10.0± 1.3a 67.6± 8.1 90.4± 10.9
DNA 50 5 6.9± 0.5 14.3± 1.2a 57.6± 6.2 89.7± 8.2
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; PBS, phosphate-buffered saline. aStatistical signiﬁcant difference for the respective
treatment groups/comparison, Po0.05.
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was also observed following single i.d. administration of a MIDGE-
Th1 vector encoding Hepatitis B surface antigen,21 it is in contrast
to the ﬁnding that 50 μg of tumor necrosis factor alpha-encoding
MIDGE vector are cleared from the injection site and other tissues
of mice within 24 h after intratumoral jet injection.20 This short
time to overall clearance was probably related to wider dispersion
of DNA upon multiple jet injection, the lower DNA concentration
(ﬁve jet injections of 10 μg DNA at 1 mgml− 1 versus one needle
injection of 120 μg DNA at 4 mgml− 1), as well as the rapid entry
into the blood circuit due to the high vascularization and low
retention rate of macromolecules in tumor tissue as compared
with normal skin tissue. Though only a side-by-side comparison
would be conclusive, we propose that these parameters strongly
affected the time to overall clearance than the DNA dose. In fact,
the rats in our study received up to 0.6 μg LEISHDNAVAX DNA per
gram body weight, thus a lower relative DNA dose than that
administered to mice of the referenced study (~1.6 μg tumor
necrosis factor alpha MIDGE DNA per gram body weight).20
A persistence of at least 60 days as observed in our study
suggests that vector DNA had entered long-living cells residing in
the skin. Whether or not this vector DNA is still functioning cannot
be concluded from our results, as the quantitative PCR method
targeted a short consensus sequence only.
Notably, MIDGE-Th1 vector DNA did not accumulate in any
tissue after repeated injections. At 60 days after one injection21 or
after four injections of LEISHDNAVAX, comparable amounts of
MIDGE-Th1 vector DNA were found, indicating that repeated
injections do not enhance persistence. Therefore, future evalua-
tions of biodistribution and persistence of MIDGE-Th1 vectors in
similar settings can be based on a single injection.
Long-term persistence of vector DNA in tissues can be related
to integration into host genomic DNA and thus, theoretically bears
tumorigenic potential. However, published data show that the
integration rate of plasmid DNA vectors does not exceed the rate
of spontaneous mutation events within the host genome.26,27,30
Notably, for linear DNA vectors with a structure similar to MIDGE
vectors a very low level of integration has been described.31
Furthermore and in contrast to closed circular plasmid DNA
molecules, integration of covalently closed linear DNA constructs
rather leads to disruption of chromosomes followed by apoptosis
of affected cells, hence minimizing the risk of replicating
unwanted genetic rearrangements.32 On the basis of these
published results, the risk related to potential integration of
MIDGE-Th1 vectors into host genomic DNA can be considered as
low, though it was not assessed in this work.
In a repeated-dose toxicity study in naive mice, we tested three
ascending doses of LEISHDNAVAX. The highest dose of 100 μg
corresponds to a human dose of ~ 300mg DNA on a mg kg− 1
body weight base. Doses in published clinical trials ranged from
0.1 mg33 to 4 mg34 of plasmid DNA, so our study design includes a
high safety margin. To further extend the safety margin, the
vaccine was administered in a condensed schedule of ﬁve
vaccinations (one more than the estimated maximum number
for clinical application) in weekly intervals. Importantly, a No
Observed Adverse Effect Level, that is, the highest dose without
signiﬁcant toxicity, was not reached with the doses tested. No
local intolerance reactions related to the vaccine were observed.
The results established in naive mice are corroborated by safety
data obtained from the biodistribution study. Rats received 120 μg
LEISHDNAVAX, corresponding to a human dose of ~ 24mg (based
on mg kg− 1 body weight). There were no vaccine-related toxic
effects observed either. Our results further conﬁrm the ﬁndings of
other investigators reporting excellent preclinical safety proﬁles of
DNA vectors.10,11,20,26,27,30
In Leishmania-infected and diseased individuals, tolerability of
the vaccine may be different than in healthy, naive vaccinees.
Moreover, owing to the ability of Leishmania amastigotes to
exploit host IgG as virulence factor,35 there is the theoretical risk of
vaccine-related immune-enhancement of infection and pathogen-
esis as discussed for other infectious diseases.36,37 Hence
demonstration of absence of disease exacerbation was included
into the development program of LEISHDNAVAX. We evaluated
the tolerability of LEISHDNAVAX in two different mouse strains,
chosen for their inherent differences in cytokine responses to
infection with L. donovani.38 These experiments demonstrate that
LEISHDNAVAX had no effect on the kinetics of the parasite burden
with no vaccine-related enhancement of infection at any of the
time points investigated. The kinetic of infection corresponded to
the well-documented pattern in mice with a rapid increase in
hepatic parasite burden, followed by a decline in parasite numbers
and clearance and a slower increase in parasite numbers in the
spleen with the establishment of chronic infections.23 Results for
all other standard parameters were similar for treated and non-
treated mice, demonstrating a good tolerability of the vaccine
candidate in infected animals.
In summary, we have shown here that LEISHDNAVAX, a novel
DNA vaccine candidate against leishmaniasis is safe and well
tolerated in both naive and Leishmania-infected mice. After
repeated i.d. injections, the vaccine was rapidly cleared from
most organs and tissues of rats and persisted in the skin of
injection site and its draining lymph nodes only. We conclude that
LEISHDNAVAX has a favorable safety proﬁle that supports the
initiation of human clinical trials.
MATERIALS AND METHODS
Vaccine
LEISHDNAVAX is an equimass mixture of ﬁve MIDGE-Th1 vectors, dissolved
in sterile PBS. Each vector encodes one Leishmania antigen: KMP11, CPA,
CPB, P74 or TSA, respectively. Their DNA sequences and expression
cassettes of MIDGE-Th1 vectors have been described previously.22 MIDGE-
Th1 vectors were synthesized in a simple and standardized procedure.18
LEISHDNAVAX was prepared at concentrations of 0.4, 2.0 and 4.0 mgml− 1
of total DNA in PBS in a controlled process with subsequent quality control
at Mologen AG (Berlin, Germany). The vaccine was ﬁlled as ready-to-use
solutions in injection vials and sent frozen to test facilities.
Biodistribution and persistence study
Aurigon Life Science (Tutzing, Germany) performed the in-life phase in
accordance with Good Laboratory Practice (GLP) Regulations and in
accordance with German animal welfare regulations. The experimental
design was reviewed and approved by the local government (Government
of Upper Bavaria, Maximilianstraße 39, 80538 München, Amt für
Verbraucherschutz und Veterinärwesen; Registration no. AZ55.2-1-
542532.2-14/07, study no.: 103.261.2895).
Forty Wistar rats (20 per sex, Janvier Labs, Saint-Berthevin, France),
8 weeks of age, were allocated to single- or four-dose study groups with 10
animals each (ﬁve per sex). Animals received needle injections of 120 μg
LEISHDNAVAX per injection (~5.3 × 1013 MIDGE-Th1 vector molecules,
injection volume 30 μl) i.d. at the dorsal base of tail, either once or four
times in weekly intervals. Animals injected with a single dose were killed
24 h after administration. Four-dose groups were either killed 24 h, 14 days
or 60 days after the fourth injection. Clinical signs were recorded before,
30min and 4 h after treatment, thereafter once daily. Twenty-four hours
after injection, a modiﬁed Irwin test39 was performed on the single-dose
group and on a non-treated control group to assess acute neurological
toxicity of the vaccine. Throughout the study, mortality was evaluated
once daily and body weight once weekly. At killing, animals were
anesthetized deeply by isoﬂurane inhalation and blood was collected from
the plexus ophthalmicus. Gross pathology was performed and samples of
the following tissues were taken: blood, thigh bone marrow, brain, heart,
kidneys, liver (Lobus quadratus), lymph nodes (Lnn. axillares, inguinales,
mesenteriales), lung, thigh muscle, ovaries, skin of injection site, spleen and
testes. To avoid cross-contamination with vector DNA single-use scalpels
were applied for each sample. All other equipment was thoroughly de-
contaminated after each dissection. Samples were immediately frozen in
liquid nitrogen and stored at − 80 °C until processing.
Quantitative analyses of DNA vector amounts were performed at IMGM
Laboratories (Martinsried, Germany). Total DNA was extracted from
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~20mg tissue or up to 280 μl blood, respectively, using the DNeasy
Blood&Tissue Kit (Qiagen, Hilden, Germany) and stored at − 20 °C.
A TaqMan-based quantitative realtime-PCR assay was established and
characterized using a standard curve of LEISHDNAVAX ranging from 10
vector copies per reaction to 1.05 × 1011 vector copies per reaction with
200 ng genomic DNA from the livers of naive animals as background.
Measurements were carried out with 200 ng of extracted total DNA in 384
well plates with a reaction volume of 20 μl on an AB7900HT instrument
(Life Technologies, Carlsbad, CA, USA). Primers (Euroﬁns Genomics,
Ebersberg, Germany) and hydrolysis MGB probe (Life Technologies) were
designed to detect a consensus sequence present on each MIDGE-Th1
vector. The forward primer (5′-GTCGTTTAGTGAACCGTCAGATCA-3′)
anneals to the CMV promoter region, the hydrolysis MGB probe (5′-FAM-
TTTATTGCGGTAGTTTATCA-NFQ-3′) and the reverse primer (5′-GCACG
ACTGCGTTAGCAATTTAA-3′) anneal to the intron. Limit of detection and
lower limit of quantiﬁcation of the assay were determined at 525 copies of
MIDGE-Th1 vector per reaction (that is, 2625 copies per μg total DNA). All
samples of extracted DNA were measured in triplicates. MIDGE-Th1 vector
copy numbers were calculated according to the LEISHDNAVAX standard
curve running in parallel on each plate and expressed as copy number per
μg total DNA. Acceptability criteria of measurements included standard
curve coefﬁcient of correlation ⩾ 0.95 and detected copy numbers of
No-template-controls below the limit of detection. In addition, the s.d. of
the quantiﬁcation cycle values of at least two replicate measurements had
to be below 0.5, otherwise the measurement was repeated.
Toxicity study in naive mice
Assessment of vaccine toxicity. The study was performed in accordance
with GLP Regulations principles and German animal welfare regulations at
LPT Laboratory of Pharmacology and Toxicology, Hamburg, Germany with
prior approval by LPT’s institutional animal care and use commissary (study
no. 26814) and by the competent authority (Behörde für Gesundheit und
Verbraucherschutz, Amt für Verbraucherschutz Lebensmittelsicherheit und
Veterinärwesen, Billstraße 80, 20539 Hamburg, Germany, V 11307-591-
00.33).
One hundred and forty BALB/c mice (70 male, 70 female) were
randomized and allocated to study groups. Animals were housed
individually. At ﬁrst treatment mice were 44–49 days (males) or 60–65 days
(females) of age with a body weight of 18.2–22.5 g (males) or 18.0–20.4 g
(females). Ten animals each (ﬁve per sex) received one i.d. needle injection
(volume: 25 μl) into the dorsal tail base with a dose of 10, 50 or 100 μg
LEISHDNAVAX or the placebo (PBS). They were killed 24 h post injection for
evaluation of acute toxic reactions. Thirty animals each receiving placebo
and 100 μg dose, or 20 animals each receiving 10 μg and 50 μg dose
(injection volume: 25 μl) were injected by needle i.d. into the dorsal tail
base ﬁve times in weekly intervals. Animals were killed after a recovery
period of 24 h, 14 days or 61 days (placebo and 100 μg dose group only)
following the ﬁfth injection (Table 1).
Animals were observed for clinical signs including injection site
reactogenicity before and 30min and 4 h after each dosing and daily
between injections. Mortality was evaluated twice daily throughout the
study. Body weight of animals was recorded at day of group allocation, on
the day of ﬁrst dosing and three times a week thereafter. Food
consumption was determined weekly and water consumption was
recorded daily. Neurological screening40 and assessment of grip
strength41 was conducted on all animals 24 h after ﬁrst dosing.
Ophthalmological and auditory examinations were performed pre-dose,
at the end of the treatment period and at the end of the recovery period.
For urinalysis, mice were placed in funnel cages in groups of ﬁve per sex
and received 30ml tap water per kg body weight by gavage.
Subsequently, urine was collected for 6 h and the following parameters
were measured: volume, weight, pH, speciﬁc gravity, osmolality, protein,
glucose, bilirubin, urobilinogen, ketones, hemoglobin, nitrite, epithelial
cells, leukocytes, erythrocytes, organisms, further constituents, crystalluria.
At killing, blood was taken for clinical biochemistry (albumin, globulin,
bilirubin, cholesterol, triglycerides, creatinine, glucose, protein, urea,
calcium, alanine aminotransferase, alkaline phosphatase, α-amylase,
aspartate aminotransferase, creatine kinase, glutamate-dehydrogenase,
γ-glutamyl-transferase, lactate dehydrogenase) and hematology
(hemoglobin content, erythrocytes, leukocytes, differential blood count,
reticulocytes, platelets, mean platelet volume, red cell distribution width,
hematocrit, mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration).
Gross pathological examination was conducted, organ weights were
taken and samples of the following organs and tissues processed
for histological examination: adrenal gland, aorta abdominalis, bone
(os femoris with joint), bone marrow, brain, cecum, coagulating gland with
seminal vesicle, epididymis, eye with optical nerve and Harderian gland,
exorbital lacrimal gland, gall bladder, heart, skin and subcutaneous tissue
of injection site, large intestine, small intestine, kidney and ureter, liver,
lung, lymph nodes (mandibular, mesenteric), mammary gland, muscle,
sciatic nerve, esophagus, ovary, pancreas, pituitary gland, prostate, salivary
glands, spinal cord, spleen, sternum, stomach, testicle, thymus, thyroid,
tongue, trachea, urinary bladder, uterus and vagina.
Histological examination was performed on samples of all animals with
the highest expected burden, that is, after receiving ﬁve injections of each
100 μg LEISHDNAVAX and 24 h of recovery, and the respective placebo
group as control. Moreover, the immunologically relevant organs thymus,
spleen and lymph nodes as well as the skin at the injection site of all
animals of all groups were examined histologically. In general, tissue
samples were ﬁxed in 7% buffered formalin (eyes in Davidson´s solution),
embedded in parafﬁn, sections prepared and routinely stained with
haematoxylin-eosin.
Samples from mice receiving ﬁve times a dose of 10 or 50 μg,
respectively, were scheduled for histologically examination only in case
of vaccine-related ﬁndings in the group receiving ﬁve times 100 μg, or if
gross pathology revealed vaccine-related changes. As there were no
respective ﬁndings, these samples were not histologically examined.
Biologic activity of the vaccine lot and assessment of antibodies against
dsDNA. In all, 100 BALB/c mice (50 male, 50 female) were randomized
and allocated to satellite study groups of the toxicity study resembling the
repeated-dose treatment schedule (Table 1). At ﬁrst treatment, animals
were 44–49 days (males) or 60–65 days (females) of age with a body
weight of 17–19.3 g (males) or 17–18.4 (females). At study termination,
blood samples were taken and serum obtained for enzyme-linked
immunosorbent assay to test for antibodies against vaccine antigens
and for radioimmunoassay to test for antibodies against dsDNA. These
analyses were performed under non-GLP Regulations conditions.
LEISHDNAVAX-speciﬁc antibodies were detected performing an
enzyme-linked immunosorbent assay as previously described22 with minor
modiﬁcations. Plates (Nunc MaxiSorp, Thermo Scientiﬁc, Roskilde,
Denmark) were coated per well with 100 μl of 5 μgml− 1 antigen-mix
(KMP11, CPA, CPB, P74, TSA 1:1:1:1:1) in PBS (Fisher Scientiﬁc, Paisley, UK).
Recombinant proteins were obtained from Proteogenix, Oberhausbergen,
France (CPA, CPB, P74, TSA) or were kindly provided by Professor C Jaffe
(KMP11). Antigen mix was assembled at LPT. Plates were incubated
overnight at 4 °C, then washed three times with wash buffer (0.05% (v/v)
TWEEN in PBS) and subsequently blocked with assay diluent (5% (w/v)
bovine serum albumin (Sigma Aldrich, St Louis, USA) in PBS) for 1 h at
room temperature. Plates were washed three times with wash buffer and
100 μl per well of 1:50 diluted serum samples were added. The plates were
incubated for 2 h at room temperature and subsequently washed ﬁve
times with wash buffer. Hundred micolitre per well of anti-mouse IgG-HRP
(Conc.: 11.3 mgml− 1), (Sigma Aldrich) were added at a 1:5000 dilution and
plates were incubated for 2 h at room temperature. After washing ﬁve
times developer solution containing 3,3’,5,5’-tetramethylbenzidine (Sigma
Aldrich) was added and the reaction stopped by adding acid solution
when the color developed. Absorbance was measured at 450 nm.
To assess the induction of an immune response against dsDNA a
radioimmunoassay was performed at IBL International GmbH (Hamburg,
Germany) using a kit for detection of anti-dsDNA antibodies (IBL
International). In brief, 25 μl of serum sample was mixed with 150 μl of
125I-labeled dsDNA tracer and incubated at 37 °C for 60min. Subsequently,
1 ml of cold ammonium sulfate solution was added to the sample followed
by vortexing. Tubes were centrifuged (15 min at 1500 g) and supernatant
was removed. Radioactivity was counted using a gamma counter and the
dsDNA binding capacity was calculated according to a standard curve.
Evaluation of vaccine tolerability in mouse models of
experimental VL
Experiments on infected animals were carried out under UK Home Ofﬁce
license PPL70/6997 following local ethical approval by the London School
of Hygiene & Tropical Medicine and the Royal Veterinary College, London.
Parasite and animal maintenance. BALB/cAnNCrl (H2d), C57BL/6J (H2b)
and Rag-1 (B6) KO mice (Charles River, Margate, UK) were maintained
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under speciﬁc pathogen-free conditions in individually ventilated cages
and exposed to 12 h light—12 h dark cycles. Standard rodent diet (RM No
1 Expanded) and de-ionized water were supplied ad libitum. L. donovani
(strain MHOM/ET/67/HU3) was maintained in Rag-1 (B6) KO mice and
amastigotes harvested from spleens of infected animals 440 days after
infection.
Infection and treatment schedule. Female BALB/c and C57BL/6 mice (6–
8 weeks of age at the start of experiments) were infected by injecting
2× 107 freshly harvested L. donovani amastigotes intravenously into a tail
vein as described.42 Following infection, animals were sorted into groups
of three to ﬁve mice per cage and two cages assigned to each treatment
group. Groups of mice received either one, two or three injections of
LEISHDNAVAX containing 20 μg DNA/antigen (corresponding to 100 μg
total DNA) or PBS, administered in volumes of 25 μl i.d. at the base of the
tail using 29G single-use needles (BD Microﬁne Plus Insulin Syringes). The
ﬁrst dose was administered 7 days after infection and repeat doses in
7-day intervals. Groups of mice were killed 7 days after having received the
last dose of LEISHDNAVAX or PBS. In a further experiment in C57BL/6 mice
additional groups were killed 29 days after the last of a total of three doses
of LEISHDNAVAX or PBS.
Determination of efﬁcacy and tolerability parameters. Mouse weights were
recorded prior to the ﬁrst dose of treatments administered and in weekly
intervals thereafter. The injection site was monitored following adminis-
tration of treatments and animals were observed daily by trained staff for
the whole duration of the experiments. Mice were humanely killed by
exsanguination under terminal anesthesia and blood collected by cardiac
puncture. Livers and spleens were removed and their weight recorded.
Tissue impression smears were prepared, ﬁxed in 100% methanol and
stained in 10% Giemsa. Parasite burden was determined microscopically
and Leishman-Donovan Units calculated by the formula number of
parasites per host cell nucleus × organ weight in mg, as described
previously.43 Serum was harvested from blood stored overnight at 4 °C
by centrifugation at 1500 g, 4 °C for 15min and stored at − 80 °C.
Biochemical analysis of standard serum parameters was carried out by
LABOKLIN GmbH&Co.KG (Bad Kissingen, Germany). For histology, organs
were ﬁxed in 10% neutral buffered formalin, embedded in parafﬁn and
routinely stained with hematoxylin and eosin. Histological data were
evaluated in blinded fashion.
Statistical methods
Data from the repeated-dose toxicity study in naive mice were analyzed
using Student's t-test for numerical functional tests (P⩽ 0.01), Dunnet's
multiple t-test for body weight, food consumption, hematology, clinical
biochemistry and organ weights (P⩽ 0.01) and Fisher's exact test for
histology (P⩽ 0.05), respectively.
Toxicity data of the biodistribution study were evaluated as follows:
parameters of the Irwin test were analyzed by Mann–Whitney U-test
(P⩽ 0.05) and normality of body weight data by Shapiro–Wilks test. In case
of normality, an analysis of variance was performed with post hoc
Dunnett’s test for multiple comparisons; otherwise, a non-parametric
Kruskal–Wallis test with post hoc Dunnett’s test was employed (P⩽ 0.05).
IgG levels were statistically analyzed using GraphPad Prism 5 (GraphPad
Software Inc., La Jolla, USA). Normality of data was tested with Shapiro-Wilk
test prior to applying either two-tailed Student’s t-test or Mann–Whitney
test to analyze differences between means of two groups (P⩽ 0.05).
To evaluate tolerability of the vaccine in infected mice, comparisons
between three or more groups were made by one-way analysis of variance
followed by Bonferroni’s multiple comparison’s test with comparison
between PBS and vaccine treated groups. Comparisons between two
groups were made by an unpaired t-test assuming Gaussian distribution
(GraphPad Prism 6). A P-value of o0.05 was considered statistically
signiﬁcant.
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